<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Time course of loop and thiazide diuretic-induced electrolyte complications</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Time course of loop and thiazide diuretic-induced electrolyte complications</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Time course of loop and thiazide diuretic-induced electrolyte complications</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">D Craig Brater, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David H Ellison, MD, FASN, FAHA</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Emmett, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Therapy with a loop- or thiazide-type diuretic may be associated with a variety of fluid and electrolyte complications, including volume depletion, azotemia, hypokalemia, metabolic alkalosis, hyponatremia, hyperuricemia, and hypomagnesemia [<a href="#rid1">1</a>]. In addition, the potassium-sparing diuretics (<a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a>, <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">triamterene</a>, mineralocorticoid receptor antagonists) can induce hyperkalemia and metabolic acidosis, while carbonic anhydrase inhibitors such as <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">acetazolamide</a> can cause hypokalemia and metabolic acidosis.</p><p>What is underappreciated is the time course with which these complications occur, which has been best studied with loop and thiazide diuretics. Assuming that the diuretic dose and dietary solute (eg, sodium and potassium) and water intake are relatively constant and that the patient is hemodynamically stable, most of the above problems develop during the first two to three weeks of therapy if they are going to occur (<a class="graphic graphic_figure graphicRef74940" href="/z/d/graphic/74940.html" rel="external">figure 1</a>) [<a href="#rid1">1-3</a>]. The reason for this time limitation is that the initial solute and water losses lead to compensatory changes that limit further losses. Thus, after the initial period of solute and water loss, a new steady state is attained in which solute and water intake and excretion are roughly equal, as they were before diuretic therapy was initiated. This phenomenon has been called <strong>diuretic braking</strong>. (See  <a class="medical medical_review" href="/z/d/html/2307.html" rel="external">"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)", section on 'The steady state'</a>.)</p><p>However, thiazide-induced hyponatremia is one exception to this time course. Although early studies suggested that thiazide-induced hyponatremia occurs within 14 days of drug initiation [<a href="#rid4">4</a>], later studies have suggested a much wider range. As an example, a retrospective cohort study involving 1275 individuals found that the median time to hyponatremia was 1.75 years [<a href="#rid5">5</a>]. Similarly, a systematic review found that, although the mean time to hyponatremia was 19 days, the time of onset varied from 1 day to 3650 days [<a href="#rid6">6</a>]. The wide variability of the time course for hyponatremia associated with thiazide diuretics may reflect the many mechanisms for altered water balance that occur in patients taking thiazides. (See  <a class="medical medical_review" href="/z/d/html/2288.html" rel="external">"Diuretic-induced hyponatremia"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">SODIUM AND WATER LOSSES</span><span class="headingEndMark"> — </span>The initial sodium and water losses induced by diuretic therapy lead to increases in a variety of sodium-retaining factors, such as angiotensin II, aldosterone, and norepinephrine, as well as to a possible reduction in systemic blood pressure [<a href="#rid2">2,7</a>]. These sodium-retaining forces eventually equal the sodium-wasting activity of the diuretic. When this occurs, there is a new steady state in which sodium and water intake and excretion are roughly equal. There will be no further diuresis (unless the diuretic dose or frequency is increased). With loop diuretics, the extracellular fluid volume will remain reduced by the amount of sodium lost during the first few days of therapy. With thiazide diuretics, the initial salt and water losses are typically followed by a period of positive salt and water balance, returning the extracellular fluid volume near (but not to) basal levels. The mechanisms responsible for this secondary response are not clear. (See  <a class="medical medical_review" href="/z/d/html/3860.html" rel="external">"Use of thiazide diuretics in patients with primary (essential) hypertension", section on 'Antihypertensive mechanism'</a>.)</p><p>In addition to the acute neurohumoral responses, structural adaptations also contribute to the compensatory sodium retention induced by chronic diuretic therapy. Studies in experimental animals show that the increase in sodium chloride delivery out of the loop of Henle that is seen with a loop diuretic leads to hypertrophy and increased sodium reabsorptive capacity in the distal and cortical collecting tubules [<a href="#rid8">8,9</a>]; with a thiazide diuretic, the increase in delivery and the subsequent hypertrophic response are limited to the connecting tubule and cortical collecting tubule [<a href="#rid9">9,10</a>]. Indirect evidence suggests that the same phenomenon occurs in humans. When compared with controls, subjects who have received a loop diuretic for one month show, after 24 hours off the diuretic, an impaired response to a loop diuretic (compatible with increased sodium reabsorption at some other site in the nephron) and an enhanced response to a thiazide diuretic (suggesting increased sodium reabsorption at a thiazide-sensitive site, presumably the distal tubule) (<a class="graphic graphic_figure graphicRef53198" href="/z/d/graphic/53198.html" rel="external">figure 2</a>) [<a href="#rid11">11</a>].</p><p>Although these observations have primarily been obtained in nonedematous patients with hypertension [<a href="#rid2">2,7</a>], the same principles apply to edematous states such as heart failure [<a href="#rid3">3</a>]. However, the time to reattainment of the steady state may be delayed in those patients on the flat part (rather than the ascending limb) of the Frank-Starling curve (<a class="graphic graphic_figure graphicRef58693" href="/z/d/graphic/58693.html" rel="external">figure 3</a>). In this setting, initial fluid loss will lower intracardiac filling pressures but not the cardiac output. As a result, the counterregulatory hormonal responses will not be activated, and the diuresis will continue until forward output begins to fall [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/3512.html" rel="external">"Use of diuretics in patients with heart failure"</a> and  <a class="medical medical_review" href="/z/d/html/3506.html" rel="external">"Pathophysiology of heart failure with reduced ejection fraction: Hemodynamic alterations and remodeling", section on 'Pressure-volume relationships in HF'</a>.)</p><p>The patient is in sodium balance in the new steady state, but the pattern of daily sodium excretion is altered: sodium will be lost during the period that the diuretic is acting, while sodium excretion will be very low for the remainder of the day due to increased activity of the sodium-retaining forces [<a href="#rid7">7</a>]. Although subject to some error [<a href="#rid13">13</a>], a 24-hour urine collection can be obtained to assess compliance with dietary sodium restriction (since daily sodium excretion will be roughly equal to intake if the patient's weight is stable), but measurement of the urine sodium concentration in a random urine specimen (often called a "spot" urine) will often be misleading, varying with the time since the diuretic dose. (See  <a class="medical medical_patient" href="/z/d/html/2181.html" rel="external">"Patient education: Collection of a 24-hour urine specimen (Beyond the Basics)"</a>.)</p><p>One other characteristic resulting from activation of sodium-retaining forces is that the maximal natriuretic response to an intravenous diuretic is seen with the <strong>first dose</strong>; even with continuous intravenous infusion of a loop diuretic, for example, the natriuresis usually begins to diminish within the first 12 hours (<a class="graphic graphic_figure graphicRef122307" href="/z/d/graphic/122307.html" rel="external">figure 4</a>) [<a href="#rid14">14</a>]. This principle also applies to oral therapy, assuming there is no defect in drug absorption. (See  <a class="medical medical_review" href="/z/d/html/2324.html" rel="external">"Causes and treatment of refractory edema in adults"</a>.)</p><p>The sequence is somewhat different in patients who are markedly volume expanded due to primary renal sodium retention (eg, in acute glomerulonephritis or acute or chronic kidney disease). In this setting, the renin-angiotensin system is suppressed and will not be activated by initial sodium loss, since hypervolemia persists. Thus, the second and subsequent doses may produce as large a natriuresis as the original dose until most of the excess fluid has been removed. Even in this setting, however, the first dose still represents the maximum response that will be seen.</p><p class="headingAnchor" id="H3"><span class="h1">POTASSIUM LOSSES</span><span class="headingEndMark"> — </span>Considerations applicable to sodium losses also apply to other diuretic-induced losses, including that of potassium. The development of hypokalemia will limit further potassium losses (<a class="graphic graphic_figure graphicRef74940" href="/z/d/graphic/74940.html" rel="external">figure 1</a>), an effect that is mediated in the aldosterone-sensitive distal nephron both by decreased potassium secretion by principal cells and increased potassium reabsorption in the intercalated cells. However, the kaliuresis may persist for several days longer than the natriuresis [<a href="#rid15">15</a>] since the inhibitory effect of hypokalemia will be counterbalanced by the hypovolemia-mediated rise in aldosterone secretion. (See  <a class="medical medical_review" href="/z/d/html/2305.html" rel="external">"Evaluation of the adult patient with hypokalemia"</a>.)</p><p>Potassium supplementation is infrequently needed when loop or thiazide diuretics are used alone but is much more likely to be required when used in combination. Whether or not to empirically treat patients initiated on loop or thiazide diuretics is unclear. In one large cohort of approximately 650,000 patients initiated on loop diuretics, a simultaneous prescription for potassium supplementation was associated with a reduction in the eight-year relative risk of death of 7 and 16 percent among those treated with &lt;40 and &gt;40 mg/day of <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a>, respectively [<a href="#rid16">16</a>]. Although further study is needed, it is important to monitor for and treat hypokalemia in patients treated with diuretics.</p><p class="headingAnchor" id="H185395927"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Therapy with a diuretic may be associated with fluid and electrolyte complications. This primarily involves volume depletion, azotemia, and hypokalemia, but metabolic alkalosis, hyponatremia, hyperuricemia, and hypomagnesemia may also occur. Assuming that the diuretic dose and dietary and water intake are relatively constant and that the patient is hemodynamically stable, most of these problems, except for hyponatremia, develop during the first two to three weeks of therapy. Thiazide-associated hyponatremia may occur much later and therefore requires ongoing monitoring. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The initial sodium and water losses induced by diuretic therapy lead to increases in a variety of sodium-retaining factors, which eventually equal the sodium-wasting activity of the diuretic. When this occurs, there is a new steady state. There will be no further diuresis, but the extracellular fluid volume will be reduced by the amount of sodium lost during the first few days of therapy. This persistent volume depletion accounts for the efficacy of the diuretic in the treatment of hypertension or edema. The patient is in sodium balance in the new steady state, but the pattern of daily sodium excretion is altered: sodium will be lost during the period that the diuretic is acting, while sodium excretion will be very low for the remainder of the day due to increased activity of the sodium-retaining forces. (See <a class="local">'Sodium and water losses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar considerations apply to other diuretic-induced losses, including that of potassium. The development of hypokalemia will limit further potassium losses. However, the kaliuresis may persist for several days longer than the natriuresis. (See <a class="local">'Potassium losses'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.453.</li><li><a class="nounderline abstract_t">Bock HA, Stein JH. Diuretics and the control of extracellular fluid volume: role of counterregulation. Semin Nephrol 1988; 8:264.</a></li><li><a class="nounderline abstract_t">Ikram H, Chan W, Espiner EA, Nicholls MG. Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. Clin Sci (Lond) 1980; 59:443.</a></li><li><a class="nounderline abstract_t">Sonnenblick M, Friedlander Y, Rosin AJ. Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. Chest 1993; 103:601.</a></li><li><a class="nounderline abstract_t">Leung AA, Wright A, Pazo V, et al. Risk of thiazide-induced hyponatremia in patients with hypertension. Am J Med 2011; 124:1064.</a></li><li><a class="nounderline abstract_t">Barber J, McKeever TM, McDowell SE, et al. A systematic review and meta-analysis of thiazide-induced hyponatraemia: time to reconsider electrolyte monitoring regimens after thiazide initiation? Br J Clin Pharmacol 2015; 79:566.</a></li><li><a class="nounderline abstract_t">Wilcox CS, Guzman NJ, Mitch WE, et al. Na+, K+, and BP homeostasis in man during furosemide: effects of prazosin and captopril. Kidney Int 1987; 31:135.</a></li><li><a class="nounderline abstract_t">Ellison DH, Velázquez H, Wright FS. Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion. J Clin Invest 1989; 83:113.</a></li><li><a class="nounderline abstract_t">Stanton BA, Kaissling B. Adaptation of distal tubule and collecting duct to increased Na delivery. II. Na+ and K+ transport. Am J Physiol 1988; 255:F1269.</a></li><li><a class="nounderline abstract_t">Garg LC, Narang N. Effects of hydrochlorothiazide on Na-K-ATPase activity along the rat nephron. Kidney Int 1987; 31:918.</a></li><li><a class="nounderline abstract_t">Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 1989; 36:682.</a></li><li><a class="nounderline abstract_t">Cox ZL, Rao VS, Ivey-Miranda JB, et al. Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure. Eur Heart J 2021; 42:4468.</a></li><li><a class="nounderline abstract_t">Lerchl K, Rakova N, Dahlmann A, et al. Agreement between 24-hour salt ingestion and sodium excretion in a controlled environment. Hypertension 2015; 66:850.</a></li><li><a class="nounderline abstract_t">Rudy DW, Voelker JR, Greene PK, et al. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Intern Med 1991; 115:360.</a></li><li><a class="nounderline abstract_t">Maronde RF, Milgrom M, Vlachakis ND, Chan L. Response of thiazide-induced hypokalemia to amiloride. JAMA 1983; 249:237.</a></li><li><a class="nounderline abstract_t">Leonard CE, Razzaghi H, Freeman CP, et al. Empiric potassium supplementation and increased survival in users of loop diuretics. PLoS One 2014; 9:e102279.</a></li></ol></div><div id="topicVersionRevision">Topic 2356 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.453.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3059429" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diuretics and the control of extracellular fluid volume: role of counterregulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7002435" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8432162" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22017784" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risk of thiazide-induced hyponatremia in patients with hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25139696" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A systematic review and meta-analysis of thiazide-induced hyponatraemia: time to reconsider electrolyte monitoring regimens after thiazide initiation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3550214" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Na+, K+, and BP homeostasis in man during furosemide: effects of prazosin and captopril.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2910903" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3202190" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Adaptation of distal tubule and collecting duct to increased Na delivery. II. Na+ and K+ transport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3035268" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effects of hydrochlorothiazide on Na-K-ATPase activity along the rat nephron.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2811065" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Mechanism of impaired natriuretic response to furosemide during prolonged therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34529781" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26259596" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Agreement between 24-hour salt ingestion and sodium excretion in a controlled environment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1863026" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6848810" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Response of thiazide-induced hypokalemia to amiloride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25029519" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Empiric potassium supplementation and increased survival in users of loop diuretics.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
